About RAPT Therapeutics
RAPT Therapeutics is a publicly listed company based in San Francisco (United States) founded in 2015. Immunology-based drugs for oncology and inflammatory diseases are developed. It operates on a Professional Services model. RAPT Therapeutics has raised $198.74 million across 7 funding rounds from investors including Kleiner Perkins, Orbimed and RTW Investments. The company has 68 employees. Its chief executive, as recorded, is Brian Wong. Its website rapt.com draws about 20 thousand monthly visits. RAPT Therapeutics offers products and services including RPT904 and CCR4 Drug Candidates. Its focus areas include Biotechnology and Immunology. Its legal entity is RAPT Therapeutics, Inc.
Company details
RAPT Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for inflammatory and immunologic diseases. The company leverages deep expertise in immunology to create molecules that modulate critical immune responses. Its lead candidate, RPT904, targets IgE for allergic conditions like food allergy and chronic spontaneous urticaria. Additionally, CCR4 drug candidates are developed for inflammation and cancer, alongside other early-stage discovery targets. The focus remains on transforming treatment landscapes in these critical healthcare sectors.
- Headquarters San Francisco, United States
- Employees 68
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website microsoft.com
- Social LinkedIn YouTube
- Legal Name Rapt Therapeutics, Inc.
- Net Profit-$129.87 M (USD)-11.19as on Dec 31, 2024
- EBITDA-$132.56 M (USD)-7.33as on Dec 31, 2024
- Total Equity Funding$198.74M (USD)
in 7 rounds
- Latest Funding Round$150M (USD), Post-IPO
Dec 2024
- InvestorsKleiner Perkins
& 13 more
- Employee Count68
Products & Services of RAPT Therapeutics
RAPT Therapeutics offers a comprehensive portfolio of products and services, including RPT904 and CCR4 Drug Candidates.
A long-acting anti-IgE antibody for allergic conditions.
Therapies targeting inflammation and cancer immune responses.
Apps and channels of RAPT Therapeutics
its YouTube channel RAPT Therapeutics has 14 subscribers and 2 videos.
Videos from RAPT Therapeutics
The most watched videos on RAPT Therapeutics's YouTube channel, RAPT Therapeutics (14 subscribers). Click a video to play it here.
More on RAPT Therapeutics.
Funding Insights of RAPT Therapeutics
RAPT Therapeutics has successfully raised a total of $198.74M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $150 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $198.74M
- Total Rounds 7
- Last Round Post-IPO — $150M
- First Round $29M
(Jun 2015)
- Investors Count 14
All 7 funding rounds of RAPT Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2024 | $150M | Post-IPO | – | TCG, TCG Crossover | |
| May 2022 | $50M | Post-IPO | – | – | – |
| Jun 2019 | $37.1M | Series C | – | TCG, Kleiner Perkins | – |
| Dec 2018 | $22.63M | Series C | – | – | – |
| Jan 2018 | $60M | Series C | – | Google Ventures | |
| May 2016 | $50M | Series B | – | TCG, Celgene | – |
| Jun 2015 | $29M | Series A | – | – | – |
14 investors in total: 14 institutional.
Investors in RAPT Therapeutics
RAPT Therapeutics has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Kleiner Perkins, Orbimed and RTW Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage investments in US life science startups are focused on. | 2007 | thecolumngroup.com | San Francisco, United States | |
| tcgcrossover.com | ||||
US private equity investments are managed by BVF Partners. | bvflp.com | San Francisco, United States | ||
Deep Track Capital is engaged in biotechnology investment activities. | deeptrackcapital.com | Greenwich, United States | ||
Multi-stage investment firm invests in healthcare and life sciences companies | foresitecapital.com | New York, United States | ||
Early-stage life science focused VC firm investing in geographies such as Europe and the US | medicxi.com | London, United Kingdom | ||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Life Sciences focused VC firm investing in the US | 2010 | rtwfunds.com | New York, United States | |
Venture capital firm investing in early-stage tech startups | 1972 | kleinerperkins.com | Menlo Park, United States |
Investor details for RAPT Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of RAPT Therapeutics
46 people are tracked at RAPT Therapeutics (19 in leadership, 13 in board & advisors, 14 in team); the tracked headcount is 68.
| Name | Role | Group |
|---|---|---|
Brian Wong | CEO | Leadership |
Amanda Rudman Spergel | Senior Medical Director, Clinical Development | Leadership |
Adnan Rahman | VP, Commercial | Leadership |
Elsa Tretter | Director Of Business Development | Leadership |
Lisa Moore | Senior Vice President Business Development & Strategy | Leadership |
David Wustrow | Sen. VP Discovery And Preclinical Development | Leadership |
William Ho | Chief Medical Officer | Leadership |
Gwen Carscadden | Chief Human Resources Officer | Leadership |
Rakesh Goyal, MD, MRCP | Medical Director | Leadership |
Joel Fernandes | Vice President, Finance & Corporate Controller | Leadership |
Mohsen Sabouri, PhD | Director, Computational Biology | Leadership |
Paul Kassner | Senior Vice President, Head Of Biology | Leadership |
Jim Farmer | Vice President Clinical Operations | Leadership |
Dirk Brockstedt | Chief Scientific Officer | Leadership |
Denise de Almeida Nagata | Associate Director, Clinical Biomarkers, Allergy And Inflammation | Leadership |
Keri Jolly | Director, Medical Writing | Leadership |
Mike Chan | Director, Program Management | Leadership |
Rodney Young | Chief Financial Officer | Leadership |
Rachel Ames | Associate Director, Discovery Biology | Leadership |
Alexander Rudensky | Chairman, Scientific Advisory Board | Board & advisors |
26 more people are available in the full profile.
Complete people profiles for RAPT Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of RAPT Therapeutics
RAPT Therapeutics is a publicly listed company on the NASDAQ with ticker symbol RAPT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date31 Oct 2019
- Listed onNASDAQ: RAPT
- Listed entityRAPT Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS75382E2081
- Share price$58.02 (+0.07% on the day) · 2026-03-04
- Market capitalisation$1.61B
- EPS (diluted, trailing year)$-11.07
- Volume (last session)11,125,216
- Analyst consensusNeutral
Financials of RAPT Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | -$129.9M | -$132.6M | |
| 2023 | -$116.8M | -$123.5M | |
| 2022 | $1.5M | -$83.8M | -$83.0M |
| 2021 | $3.8M | -$69.2M | -$68.2M |
| 2020 | $5.0M | -$52.9M | -$52.1M |
Detailed financial statements for RAPT Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of RAPT Therapeutics
4 dated milestones of RAPT Therapeutics across 9 years, from founding to its latest funding, stage changes and deals.
- Founded RAPT Therapeutics is founded.
- Funding First funding round of $29.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $150.0M.
Web traffic of RAPT Therapeutics
The website of RAPT Therapeutics (rapt.com) receives about 20K visits a month.
- Monthly visits20K
▲ 79.7% vs previous month
Websites whose visitors overlap most with RAPT Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| clinicaltrialsarena.com | 100% | #257,942 | View details | ||
| businessobjects.com | 43% | View details | |||
agilegraph.com | agilegraph.com | 43% | – | ||
visumap.net | visumap.net | 43% | – | ||
yellowfin.com.au | yellowfin.com.au | 43% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 21 similar websites and full traffic analytics for RAPT Therapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 21 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as RAPT Therapeutics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Rapt Therapeutics
Complete news archive for RAPT Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about RAPT Therapeutics
RAPT Therapeutics was founded in 2015.
RAPT Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Brian Wong is the CEO of RAPT Therapeutics, as recorded in our data.
RAPT Therapeutics is a funded company, having raised a total of $198.74M across 7 funding rounds to date. The company's 1st funding round was a Series A of $29M, raised on Jun 2015.
RAPT Therapeutics has 68 employees.
RAPT Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for inflammatory and immunologic diseases. The company leverages deep expertise in immunology to create molecules that modulate critical immune responses. Its lead candidate, RPT904, targets IgE for allergic conditions like food allergy and chronic spontaneous urticaria. Additionally, CCR4 drug candidates are developed for inflammation and cancer, alongside other early-stage discovery targets. The focus remains on transforming treatment landscapes in these critical healthcare sectors.
RAPT Therapeutics offers RPT904 and CCR4 Drug Candidates.
Yes, RAPT Therapeutics is publicly traded on NASDAQ under the ticker symbol RAPT.
RAPT Therapeutics has 14 investors. Key investors include Kleiner Perkins, Orbimed, RTW Investments, Celgene, and Perceptive Advisors.
RAPT Therapeutics operates through Rapt Therapeutics, Inc..